跳至主要内容
临床试验/NL-OMON39563
NL-OMON39563已完成不适用

Effect of Growth Hormone replacement therapy on cardiovascular risk factors in adult patients with severe growth hormone deficiency: association with IGF-I concentration - GH and cardiovascular risk factors

Vrije Universiteit Medisch Centrum0 个研究点目标入组 32 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
32

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Ongoing surveillance at our centre (VUmc, Amsterdam)
  • - GH treated (at least one year)
  • - Men and women with an age between 20 and 65 years, both childhood as adult onset GHD
  • - Stable substitution therapies for other pituitary hormone deficiencies

排除标准

  • - Subjects with a craniopharyngioma as cause of their GHD or pituitary deficiencies
  • - Contraindications for the use of Growth Hormone treatment
  • - (Receiving treatment for) malignant disease (in the past)
  • - Cardiovascular event less than one year prior to inclusion
  • - Participation in other studies
  • - Subjects, who in the opinion of the investigator, are unsuitable in any other way to participate in this study

研究者

相似试验